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50 Poster Session IThe median follow up is 13.5 months (15.2 months among survi-
vors, range 4.1–22.3 months). 100-day treatment-related mortality
was 10.3%, without any VOD or TMA. One and two year relapse-
free survival is 56.9% and 45.6% and overall survival is 74.8% and
69.8% at 1 and 2 years. Causes of death include sepsis(4), relapse(2),
and EBV-PTLD(2). Chimerism analysis at day 100 (n 5 23) re-
vealed complete single cord chimerism in 13 subjects with mixed
chimerism in 10. The first infused unit was the predominant unit
at day 100 in 15/23 subjects. There was no correlation between
cord dominance and HLA match, TNC/kg or CD341 cell count.
Conclusions: This study demonstrates excellent engraftment after
DUCBT using a reduced-intensity conditioning regimen. The risk
of acute and chronic GVHD are low when sirolimus and tacrolimus
are used as GVHD prophylaxis, and survival is comparable to his-
torical unrelated donor cohorts.131
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Killer Ig-like receptors (KIRs) are expressed on human NK and
T cell subsets. KIRs transmit either inhibitory or activating signals
regulating cell activities. Some inhibitory KIRs specifically recog-
nize HLA-A, B, or Cw allotypes on target cells as inhibitory KIR
ligands (iKIRLs). Most activating KIR ligands have not yet to be
well defined. We have analyzed the known iKIRLs and KIR geno-
types in 544 primary allogeneic HCTs with T-replete grafts from
unrelated or HLA mismatched related donors. There were 159
transplants with class I antigen level mismatched donors; 79 cases
were without also being iKIRL mismatched; 80 cases were mis-
matched for the iKIRLs. The latter group had inferior overall sur-
vival (HR: 1.79; P 5 0.003), and event-free survival (HR: 1.86; P
5 0.001). Both relapse (HR: 1.90; P 5 0.03) and non-relapse mor-
tality (HR: 1.83; P 5 0.01) contributed to the inferior survival of
the group that were mismatched for both Class I and iKIRLs. The
detrimental effect was also evident when 8/8 antigen-matched
transplants (385) were analyzed for patients lacking iKIRLs. Over-
all survival in patients (218) lacking the HLA-Cw Group-1 or 2
iKIRL was significantly lower than that in patients (167) having
the iKIRLs, (HR: 1.39; P 5 0.02). Patients lacking iKIRLs had
higher non-relapse mortality (HR: 1.50; P 5 0.03). KIR genotype
data are available for 360 cases so far. Our algorithm calculates
a score based on the KIR genotype of the patient compared to
the KIR genotype of the donor. In 360 cases the score was found
to be predictive of the incidence of aGVHD (Table). Multivariate
analyses confirmed that both iKIRLs and KIR genotype scores
were independent factors affecting HCT outcomes. In T-replete
HCT, iKIRL mismatches, as well as the absence of iKIRLs confer
higher risk of a poor outcome. The algorithm for KIR genotype
scoring produces results that are predictive of the incidence of
aGVHD.
Correlation of SCORE and aGVHD
aGVHDScore 0 I II III IV III1(%).1 12 5 12 14 8 43
1 15 12 19 10 18 38
0 to 21 41 40 34 28 21 30
\21 34 12 12 8 7 21Chi Square test 5 0.00271.132
IMPROVED OUTCOMES OF PATIENTS WITH AML/MDS UNDERGOING
HAPLOIDENTICAL STEM CELL TRANSPLANTATION USING FLUDARA-
BINE, MELPHALAN AND THIOTEPA CONDITIONING CHEMOTHERAPY
Ciurea, S.O., Quareshi, S., Rondon, G., McMannis, J., Pesoa, S.,
Cano, P., Fernandez-Vina, M., Giralt, S., de Lima, M.,
Champlin, R.E., Gajewski, J. The University of Texas MD Anderson
Cancer Center, Houston, TX.
Background: Total body radiation (TBI) conditioning is associ-
ated with substantial toxicity in patients (pts) undergoing haploi-
dentical stem cell transplantation (HaploSCT). We evaluated
a chemotherapy-only reduced-intensity conditioning (RIC) regi-
men to elicit engraftment with less toxicity in patients with AML/
MDS treated with HaploSCT and report a non-randomized com-
parison between FMT and TBI regimens for such patients.
Methods: 31 pts underwent HaploSCT with CD34-selected
PBPC. 18 pts received a RIC consisting of melphalan 140 mg/m
sq on day -8, 10 mg/m2, thiotepa on day -7, 160 mg/m2, fludarabine
on days -6, -5, -4, -3 and 1.5 mg/kg of rabbit ATG on days -6, -5, -4,
and -3 (FMT) between 10/2001–4/2007, and 13 pts who received
thiotepa 5 or 10 mg/kg on day -8, cyclophosphamide 60 mg/kg
on days -7 and -6, ATG 15 mg/kg on days -4 and -3 and TBI
3Gy/day on days -4 to -1 (CTT) between 4/1995–2/2000. The me-
dian age was 36 and 35 years respectively. Cytogenetics were poor
or intermediate-risk with the poor-risk present in 55.5% of FMT
and 43% CTT pts. At the time of transplant 61.1% of FMT and
53.8% of CTT pts had relapsed/refractory disease. Pts had 2 or
3-antigen mismatched donors with 3-antigen mismatch in 77%
FMT and 53.8% CTT pts. The numbers of CD34 cells infused
were 11 and 7.3  106/kg (p 5 0.4), and CD3 cells were 0.01 and
0.85  104/kg (p 5 0.1) in the FMT and CTT groups. 4 out of
13 pts in the CTT group also received psoralen-phototherapy
treated T-cells. Results: Median follow-up in FMT pts was 30.5
months. 77.8% and 71.4% of the pts engrafted with FMT and
CTT regimens. Grade 3–4 aGVHD occurred in 5.5% and 57.1%
(p 5 0.002) while cGVHD was found in 27.7% and 42.5%
(p5NS). Early death occurred in 1 FMT and 6 CTT pts (p 5
0.018) while day 100 TRM was 16.6% versus 53.5% (p 5 0.028).
OS was 33.3% and 14.3% (p5 0.06). 4 out of 7 (57%) FMT treated
pts in CR at the time of transplant survived as compared with 2 out
of 11 pts (18.1%) not in CR (p 5 0.03). None of the 6 pts in CR
treated with CTT survived (p 5 0.03). NRM was 33% in the
FMT group and 69% in the CTT group. 1 pt died of GVHD in
the FMT group as compared with 4 in the CTT group. Other
causes of death were disease relapse in 6 pts, organ failure and infec-
tions in 5 pts in the FMT group, while 3 pts died of recurrent disease
and 4 of infection and organ failure in the CTT group.
In conclusion, the RIC FMT regimen was an effective, less toxic
preparative regimen for patients with AML undergoing HaploSCT.133
A RETROSPECTIVE STUDY AND MATCHED PAIR ANALYSIS OF 240 PEDI-
ATRIC PATIENTS WITH MALIGNANCIES TRANSPLANTED WITH PLASMA
DEPLETED (PD) OR RED CELL REDUCED (RCR) CORD BLOOD (CB)
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Cell dosage is critical for cord blood transplantation (CBT) out-
come; therefore pediatric patients are ideal for CBT. Younger re-
cipient age is associated with better survival and neutrophil
(ANC500) engraftment. Outcome is furter improved by increasing
CB cell dose. Most CB banks practice red blood cell (RBC) reduc-
tion, which incur significant nucleated and progenitor cell loss after
processing. One way to minimize cell loss and reduce volume is to
Poster Session I 51deplete plasma, but not the RBC. A retrospective analysis was per-
formed on 240 pediatric patients transplanted with PD (128) or
RCR (112) CB. PD CB came from StemCyte and were transplanted
at many US & international centers - 60 ALL, 35 AML, 6 MDS, 5
lymphoma, 4 JMML, and 18 other malignancies. The other patients
received RCR CB products from various CB banks and were trans-
planted at the University of Arizona Medical Center - 56 ALL, 32
AML, 9 CML, 6 MDS, 4 lymphoma, and 5 other malignancies.
Of the 74% PD and 46% RCR cases with known disease status,
27% versus 24% were early, 45% versus 52% intermediate, and
27% and 18% advanced per IBMTR for PD and RCR respectively.
Median age for PD and RCR patients were 6 (range 0.5–15) and 7
years (range 0.5–15) respectively; median weight were 21 kg (range
5–92) for PD and 25 kg (range 7–104) for RCR, with 65%. and 55%
males respectively. Median # HLA ABDR matches were 5.0 for
both groups; however, median pre-freeze and post-thaw TNC
dose were 6.8  107/kg and 5.3  107/kg for PD patients (78% re-
covery) and 4.6  107/kg and 3.3  107/kg for RCR patients (72%
recovery); non-myeloablative conditioning accounted for 12% of
PD and 3% of RCR patients. Cumulative incidence estimates
were used for engraftment (unevaluable category not used), and Ka-
plan-Meier estimates were used for relapse, TRM, OS and RFS
rates. A matched-pair analysis was also performed by matching
a PD patient to each RCD patient based on age, weight, # HLA
matches, cell dose, disease, and disease status if available and are
summarized below. The results demonstrate that 1) Foregoing
RCR may result in higher cell dose products being selected for
transplantation; 2) unrelated PD CBT can be performed safely
with superior engraftment and TRM in diverse pediatric patients
with malignancies, and appear to trend towards improvement for
overall survival on univariate analysis; 3) matched pair analysis
even with cell dose matched may show a potential advantage of
PD CB for platelet engraftment and TRM.
Outcome Summary
Plt Plt 1-Yr 100-Day &ANC500 20 K 50 K Relapse* 1-Yr TRM 1-Yr OS 1-Yr RFS*PD Patients 89 ± 6% 69 ± 6% 65 ± 6% 29 ± 5% 15 ± 3%,
23 ± 4%60 ± 5% 51 ± 5%RCR Patients 85 ± 6% 55 ± 6% 51 ± 6% 17 ± 5%* 30 ± 4%,
45 ± 5%49 ± 5% 44 ± 5%*Cox RR &
P-value
(RCR
Reference)0.81 0.13 1.60 0.007 1.41 0.06 0.49 0.002 0.74 0.11
(for death)Matched Pair
AnalysisANC500 Plt 20 K Plt 50 K Relapse TRM OS RFSP-value NS 0.005 0.02 0.004 NS NSIn favor of PD PD PDNS 5 Not significant.
*Insufficient data on disease status of RCR patients precludes mean-
ingful analysis.134
CLINICAL CHARACTERISTICS OF EARLY ONSET NON-INFECTIOUS PUL-
MONARY COMPLICATIONS FOLLOWING CORD BLOOD TRANSPLANTA-
TION
Wake, A., Uchida, N., Ishiwata, K., Takagi, S., Tsuji, M., Kato, D.,
Yamamoto, H., Seo, S., Matsuno, N., Masuoka, K., Miyakoshi, S.,
Makino, S., Yoneyama, A., Taniguchi, S. Toranomon Hospital, Tokyo,
Japan.
Early onset non-infectious pulmonary complications (EONIPC),
such as idiopathic pneumonia syndrome (IPS) are fatal disorders
following allogeneic SCT. There has been little information on
NIPC following cord blood transplantation (CBT). We tried to
characterize NIPC after CBT.
We reviewed medical records of 246 patients (291 transplants)
with hematological diseases who had received CBT between Jan.2002 and Dec. 2006 at Toranomon Hospital, Tokyo, Japan. Median
age was 55 years (17–79). Most of them had diseases in advanced sta-
tus (n5 255). Most of the pre-transplant conditioning were reduced
intensity consisted of fludarabine, melphalan and TBI 4Gy (n 5
223). Most of GVHD prophylaxis were calcineurin inhibitor only;
cyclosporine (CSP) (n 5 102) or tacrolimus (Tac) alone (n 5
173). HLA disparities were as follows; 6/6 (n 5 14), 5/6 (n 5 73),
4/6 (n 5 198), and 3/6 (n 5 6). Diagnosis of NIPC was made by
Chest X-ray, computed tomography, bronchoscopy, and pulmo-
nary function test. Infectious complications were excluded by posi-
tive result of culture, galactomannan test, and RT-PCR of sputum,
pleural effusion and BAL fluid.
The incidence of NIPC was 33.7% (n 5 98). EONIPC (95 pa-
tients) were developed within 100 days after transplant (median,
17 days, range, 2–57), which can be subdivided into 2 on the basis
of presence (n 5 48) or absence (n 5 47) of pleural effusion (PE).
Late onset NIPC (LONIPC) were observed in only 11 cases
(4.5%), including 3 cases of COP, 6 of IP, and 2 of BO. Multivariate
analysis revealed 3 risk factors for EONIPC with PE; GVHD pro-
phylaxis with CSP over Tac (p 5 0.036, RR 1.65), grade III-IV
acute GVHD over grade 0-II (p 5 0.007, RR 1.84), and 2 and
greater HLA mismatch over less than 2 (p 5 0.046, RR 1.587).
The CT finding of NIPC with PE revealed ground-glass opacity
of lung field, similar to that of COP. NIPC with PE responded fa-
vorably to low dose corticosteroid therapy as same as COP. In con-
trast to low 1-year overall survival (OS) of NIPC without PE
(11.1%, 95%CI: 1.9–20.3), that of NIPC without PE was signifi-
cantly high (53.1%, CI: 38.8–67.4).
The incidence of EONIPCs was high, whereas that of LONIPCs
was low after reduced-intensity CBT using single calcineurin inhib-
itor as GVHD prophylaxis. Further accumulation and more precise
investigation of laboratory and clinical data are warranted to clarify
the biological mechanism of EONIPC with PE and without PE or
to descriminate IPS from engraftment syndrome or capillary leak
syndrome.135
A TWO STEP APPROACH TO HAPLOIDENTICAL ALLOGENEIC HEMATO-
POIETIC STEM CELL TRANSPLANTATION (HSCT) FOR HIGH RISK PA-
TIENTS WITH HEMATOLOGIC DISORDERS
Grosso, D., Brunner, J., Carabasi, M., Dessain, S., Filicko-O’Hara, J.,
Mookerjee, B., O’Hara, W., Tedesco, N., Wagner, J.L.,
Flomenberg, N. Thomas Jefferson University, Philadelphia, PA.
Post transplant cyclophosphamide (CTX) has been utilized to in-
duce donor host tolerance in allogeneic HSCT. While promising,
the long term risk of MDS and AML from exposure of the graft
to CTX is unknown, and the optimal T cell dose to deliver using
this approach remains undefined. To address these issues, 12
high-risk patients underwent haploidentical HSCT from related
donors for disorders of hematopoiesis using a two step approach.
Nine of 12 (75%) patients had evidence of disease at the time of
HSCT. In the GVH direction, 10 of 12 were 4/8 matches with their
donors at HLA-A, B, C and DRB1; the other 2 patients were 5/8
and 6/8 matches. Nine of the 12 patients were given a myeloablative
conditioning regimen of TBI (1.5 Gy) BID on days -9 through -6.
Three received a nonmyeloablative conditioning regimen of fludar-
abine and ARA-C on days-11 through -8 and one 2 Gy fraction of
TBI on day -6. The patients received 2  108/kg of their donor’s
CD31 lymphocytes after completion of TBI on day -6, followed
by rest days on day -5 and -4. On days -3 and -2, CTX was given
at a dose of 60 mg/kg/day for the purpose of tolerization of the do-
nor lymphocytes. On day 0, donor CD341 cells were infused. When
possible, the number of non-tolerized T-cells in the CD341 prod-
uct was limited to 5  104/kg. Tacrolimus and CellCept were used
as GVHD prophylaxis. All of the patients developed fevers between
DLI and CTX. Some patients also developed mild diarrhea and
a rash, which in one case was biopsy-positive for GVHD. All pa-
tients engrafted. GVHD was generally mild, and easily controlled
with corticosteroids which could be rapidly tapered in all but one
patient. Five patients have died, three of relapsed disease and two
of infections. An additional patient is alive, but with relapsed dis-
ease. Six patients are well and in CR at a range of 19–298 days
